Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.
| Excerpt | Reference |
|---|
| "Sarcopenia is the loss of muscle mass and strength which occurs with aging." | ( Arvapalli, RK; Blough, E; Gadde, MK; Gutta, AK; Kakarla, SK; Katta, A; Nalabotu, SK; Paturi, S; Rice, KM; Wu, M, 2010) |
| "The term sarcopenia is reserved for age-related decline in muscle mass not attributable to the presence of proinflammatory cytokines." | ( Thomas, DR, 2010) |
| "Although sarcopenia is well documented, the molecular mechanisms of this condition still remain unclear." | ( Béchet, D; Brulé, C; Cottin, P; Dargelos, E; Diallo, R; Listrat, A; Poussard, S, 2010) |
| "Sarcopenia is the loss of muscle size and function during ageing." | ( Alesci, S; Brady, J; Crowther, D; DeVries, A; Dhanani, T; Fearon, KC; Gilbert, F; Greig, CA; Grierson, C; Joyson, A; Ratkevicius, A; Rauchhaus, P; Redpath, TW; Reid, DM; Selmer, I; Tommasi, AM; Wackerhage, H; Yaworsky, P, 2011) |
| "Sarcopenia is defined as an age-related decrease in skeletal muscle mass and function while adjacent satellite cells are unable to compensate for this loss." | ( Blom, J; Cohen, R; Maier, AB; van Heemst, D; Westendorp, RG, 2012) |
| "Measures of sarcopenia are associated with lower cognitive functioning in older adults, and for females, this association may be partly due to systemic inflammation." | ( Canon, ME; Crimmins, EM, 2011) |
| "Age-related sarcopenia is a disease state of loss of muscle mass and strength that affects physical function and mobility leading to falls, fractures, and disability." | ( Adamski, S; Alves, SE; Chiu, CS; Flores, O; Gentile, MA; Kath, G; Rauch, A; Weber, H; Wilkinson, HA, 2011) |
| "Central sarcopenia is a marker of frailty and predicts mortality." | ( Daignault, S; Doherty, GM; Gauger, PG; Ignatoski, KM; Lindland, C; Miller, BS; Wang, SC, 2011) |
| "Sarcopenia is the age-related loss of muscle." | ( Morley, JE, 2012) |
| "Sarcopenia is considered to be an enormous burden for both the individuals affected and for society at large." | ( Bauer, JM; Dahinden, P; Drey, M; Fariello, RG; Sieber, CC; Uter, W; Vrijbloed, JW, 2013) |
| "Sarcopenia is a syndrome characterized by the progressive loss of muscle mass and strength with a risk of undesirable effects such as physical disability, poor quality of life and death, and it is a major contributing factor of disability and loss of independence in the elderly." | ( Burgos Peláez, R, 2012) |
| "Sarcopenia is a geriatric syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life, and death." | ( Ceda, GP; Lauretani, F; Maggio, M, 2013) |
| "The cause of sarcopenia is still not fully understood." | ( Bauer, JM; Drey, M; Grösch, C; Neuwirth, C; Sieber, CC, 2013) |
| "Diagnosis of sarcopenia is based on the combination of physical-performance assessment and muscle-mass measurement." | ( Harada, A; Hida, T, 2013) |
| "Sarcopenia is a relevant and predictive factor in elderly patients with DLBCL treated with rituximab plus chemotherapy." | ( Clatot, F; Jardin, F; Kraut-Tauzia, J; Lanic, H; Leprêtre, S; Mareschal, S; Modzelewski, R; Picquenot, JM; Stamatoullas, A; Tilly, H, 2014) |
| "Prevalence of presarcopenia is higher among Asian Indian subjects with type 2 diabetes compared with age- and sex-matched participants without diabetes." | ( Anbalagan, VP; Anjana, RM; Deepa, M; Mohan, V; Pradeepa, R; Venkataraman, V, 2013) |
| "Osteoporosis and sarcopenia are the most frequent musculoskeletal disorders affecting older people." | ( Baldi, J; Celi, M; Gasbarra, E; Iundusi, R; Liuni, FM; Rao, C; Tarantino, U, 2013) |
| "Sarcopenia is the progressive loss of skeletal muscle that contributes to the decline in physical function during aging." | ( Lewandowski, PA; Sullivan-Gunn, MJ, 2013) |
| "Moreover, if sarcopenia is present and information on GFR is required, this should not be measured based on creatinine only, but additional measures, such as cystatin-C, should be taken into account." | ( de Winter, CF; Echteld, MA; Evenhuis, HM, 2014) |
| "Sarcopenia is a notable and debilitating age-associated condition." | ( Barboza, J; Ceballos, G; Ciaraldi, TP; Gutierrez-Salmean, G; Henry, RR; Hogan, MC; Meaney, E; Nogueira, L; Ramirez-Sanchez, I; Taub, PR; Villarreal, F, 2014) |
| "Sarcopenia is defined as skeletal muscle loss and dysfunction in aging and chronic diseases." | ( Biolo, G; Cederholm, T; Muscaritoli, M, 2014) |
| "Sarcopenia is an age-related decline in skeletal muscle mass and function that is multifactorial in etiology." | ( Abadir, P; Chuang, YF; Lin, CH; Roy, CN; Walston, JD; Xue, QL; Yang, H, 2014) |
| "Sarcopenia is a geriatric syndrome that is characterized by gradual loss of muscle mass and strength with increasing age." | ( Abdul Karim, N; Khor, SC; Makpol, S; Ngah, WZ; Yusof, YA, 2014) |
| "Sarcopenia is the loss of skeletal muscle mass and strength that occurs with aging." | ( Choudhary, S; Dillon, EL; Horstman, AM; Sheffield-Moore, M; Tilton, RG; Urban, RJ; Zhao, Y, 2014) |
| "Sarcopenia is a defining feature of cancer cachexia associated with physical decline, poor quality of life and poor prognosis." | ( Amundsen, T; Grønberg, BH; Helbostad, JL; Hjelde, H; Kaasa, S; Stene, GB; Sørhaug, S, 2015) |
| "Sarcopenia is characterized by decreases in both muscle mass and muscle function." | ( Moore, DR, 2014) |
| "Sarcopenia is a significant predictor of DLT in oesophago-gastric cancer patients undergoing neo-adjuvant chemotherapy." | ( Brammer, K; Catton, JA; James, EJ; Parsons, SL; Randhawa, N; Tan, BH; Welch, NT, 2015) |
| "Sarcopenia is disproportionately present in older women with disability, and optimum treatment is not clear." | ( Bean, JF; Broe, K; Connerty, M; Fielding, RA; Kiel, DP; Maclean, D; Mavros, Y; O'Neill, E; Singh, MA; Taylor, A, 2015) |
| "Sarcopenia is the loss of muscle mass, strength and/or performance with age." | ( Hickson, M, 2015) |
| "Sarcopenia is an independent prognostic factor in male patients with DLBCL." | ( Goto, N; Hara, T; Kanemura, N; Kitagawa, J; Kito, Y; Matsumoto, T; Miyazaki, T; Nakamura, H; Nakamura, N; Ninomiya, S; Shibata, Y; Shimizu, M; Shiraki, M; Takeuchi, T; Tsurumi, H, 2015) |
| "Although sarcopenia is recently recognized as another complication associated with diabetes mellitus, its mechanism still remains unclear." | ( Kanazawa, I; Sugimoto, T; Tanaka, K, 2016) |
| "Sarcopenia is a degenerative syndrome mainly characterized by the atrophy of skeletal muscle, along with the decrease of muscle strength and function." | ( Gong, D; Jia, F; Liu, Z; Ren, H; Xu, B, 2016) |
| "Sarcopenia is known to be related to an increased risk of chemotherapy toxicity and to a poor prognosis in patients with malignancy." | ( Go, SI; Kang, MH; Kim, HG; Kim, RB; Kim, Y; Lee, GW; Lee, HR; Lee, SI; Park, MJ; Song, HN, 2016) |
| "Sarcopenia is associated with intolerance to standard R-CHOP chemotherapy as well as a poor prognosis." | ( Go, SI; Kang, MH; Kim, HG; Kim, RB; Kim, Y; Lee, GW; Lee, HR; Lee, SI; Park, MJ; Song, HN, 2016) |
| "Muscle depletion (sarcopenia) is associated with the occurrence of postoperative complications." | ( Ammari, S; Antoun, S; Bayar, MA; Chemama, S; Elias, D; Goéré, D; Lanoy, E; Raynard, B; Stoclin, A, 2016) |
| "Sarcopenia is associated with increased risk of treatment intolerance and may be useful in guiding treatment planning and supportive care measures." | ( Carson, KR; Ganti, A; Liu, W; Luo, S; Lynch, RC; O'Brian, K; Riedell, P; Sanfilippo, KM; Xiao, DY, 2016) |
| "Sarcopenia is associated with declining renal function, which induces lower eGFR and higher UACR." | ( Shen, X; Yan, S; Yang, R; Zhang, Y, 2016) |
| "Cachexia and sarcopenia are conditions phenotypically characterized by muscle loss and represent a factor of poor prognosis, increasing patients' morbidity and mortality." | ( Amabile, MI; Molfino, A; Muscaritoli, M; Rossi Fanelli, F, 2016) |
| "Sarcopenia is characterized by muscle mass depletion and decrease in muscle power or physical activity." | ( Kaido, T; Tamai, Y; Uemoto, S, 2016) |
| "Sarcopenia is a geriatric syndrome characterized by progressive and generalized loss of skeletal muscle mass and function." | ( Campins, L; Camps, M; Pleguezuelos, E; Riera, A; Serra-Prat, M; Yebenes, JC, 2017) |
| "Sarcopenia is associated with a poor prognosis in the ICU." | ( Frazee, EN; Herasevich, V; Kashani, KB; Kashyap, R; Kukrálová, L; Lieske, JC; Sarvottam, K; Young, PM, 2017) |
| "Sarcopenia is a condition of the loss of muscle mass that is associated with aging and that increases the risk for bedridden state, thereby warranting studies of interventions that attenuate sarcopenia." | ( Ito, Y; Nagasawa, T; Sato, T, 2017) |
| "Sarcopenia is associated with increased morbidity and mortality in chronic kidney disease (CKD)." | ( Abe, T; Ito, S; Kisu, K; Koizumi, K; Kudo, T; Kurasawa, N; Mishima, E; Miura, D; Mokudai, T; Mori, T; Morikawa-Ichinose, T; Naganuma, E; Niwa, T; Niwano, Y; Oba-Yabana, I; Oe, Y; Saigusa, D; Saito, R; Sato, E; Sato, H; Sugawara, S; Suzuki, A; Suzuki, C; Takahashi, N, 2016) |
| "Sarcopenia is defined as the loss of muscle mass associated with a loss of muscle function, e." | ( Morley, JE, 2017) |
| "Sarcopenia is the progressive loss of muscle mass and strength that occurs with advancing age and plays a pivotal role in the causal pathway leading to frailty, disability and, eventually, to death among older persons." | ( Clerici, M; Del Ry, S; Macchi, C; Molino-Lova, R; Pasquini, G; Sofi, F; Sorbi, S; Vannetti, F; Vassalle, C, 2017) |
| "Sarcopenia is known to be associated with poor clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL)." | ( Go, SI; Kang, JH; Kang, MH; Kim, HG; Kim, HR; Lee, GW; Park, MJ; Song, HN, 2017) |
| "Sarcopenia is defined as the ageing related loss of muscle mass in health and disease that may not have an effect on body weight." | ( Anker, M; Anker, SD; Doehner, W; Ishida, J; Saitoh, M; Springer, J; von Haehling, S, 2017) |
| "Sarcopenia is an aging and disease-related syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, with the risk of frailty and poor quality of life." | ( Harada, H; Ikeda, H; Kai, H; Katoh, A; Murohara, T; Niiyama, H; Nishiyama, Y; Shibata, R; Yoshida, N, 2017) |
| "Sarcopenia is defined as low muscle function (walking speed or grip strength) in the presence of low muscle mass." | ( Matsumoto, AM; McKee, A; Morley, JE; Vinik, A, 2017) |
| "Sarcopenia is the degenerative loss of core muscle mass." | ( Abeysundara, L; Christodoulidou, M; Dutta, P; Richards, T; Schofield, N; Shah, N; Wylie, S, 2017) |
| "Sarcopenia is an age-related syndrome characterized by progressive loss of muscle mass and function." | ( Chen, JL; Liao, ZY; Lv, AK; Pu, D; Sun, Y; Wang, ML; Xiao, MH; Xiao, Q; Zhao, KX; Zhao, YX; Zhou, J; Zhu, SY, 2017) |
| "Sarcopenia is recognized as a condition related to quality of life and prognosis in patients with chronic liver disease, although no useful strategy for improving muscle volume and strength has been established." | ( Abe, M; Aibiki, T; Hiasa, Y; Hiraoka, A; Hirooka, M; Iwasaki, R; Izumoto, H; Kaneto, M; Kiguchi, D; Kishida, M; Kitahata, S; Kohgami, S; Matsuura, B; Michitaka, K; Miyamoto, Y; Miyata, H; Mori, K; Ninomiya, T; Okudaira, T; Suga, Y; Tokumoto, Y; Tomida, H; Tsubouchi, E; Ueki, H; Yamago, H, 2017) |
| "Sarcopenia is defined as an age-related loss of skeletal muscle mass and function and is recognized as a major clinical problem for older people." | ( Caliari, C; D'Introno, A; Fantin, F; Gattazzo, S; Mazzali, G; Rossi, AP; Rubele, S; Zamboni, M; Zoico, E, 2017) |
| "Sarcopenia is the degenerative loss of muscle mass and strength with aging." | ( Campos, CA; Casas, M; Castro-Sepúlveda, M; Contreras-Hernández, I; Del Campo, A; Eisner, V; Figueroa, R; Jaimovich, E; Tevy, MF, 2018) |
| "Sarcopenia is the age-related degeneration characterized with the decline of skeletal muscle mass, strength, and function." | ( Ao, UI; Chan, DC; Chen, YS; Chiang, CK; Huang, JW; Hung, KY; Jheng, JR; Tarng, DC, 2018) |
| "Sarcopenia is a very common, but frequently overlooked and undertreated geriatric syndrome comprising pronounced muscle mass and strength/performance loss." | ( Keller, K, 2019) |
| "The pathogenesis of sarcopenia is complex, and many factors are involved in its development and progression." | ( Zhao, G, 2018) |
| "Sarcopenia is related to poor survival in gastric cancer patients and appears to be a significant negative prognostic factor in patients with gastric cancer who underwent curative resection." | ( Aoyama, T; Bando, E; Inano, T; Kawamura, T; Makuuchi, R; Tanizawa, Y; Terashima, M; Tokunaga, M; Yasui, H, 2018) |
| "Sarcopenia is frequently observed and associated with poor outcomes in patients with chronic kidney disease (CKD)." | ( Araki, S; Arima, Y; Fujisue, K; Hanatani, S; Ishida, T; Izumiya, Y; Kaikita, K; Kimura, Y; Kojima, S; Nakamura, T; Onoue, Y; Sakamoto, K; Sueta, D; Takashio, S; Tanaka, T; Tsujita, K; Yamamoto, E; Yamamoto, M; Yamamura, S, 2018) |
| "Myosteatosis and sarcopenia are independently associated with overt hepatic encephalopathy in patients with cirrhosis." | ( Bhanji, RA; Duarte-Rojo, A; Ebadi, M; Ghosh, S; Moctezuma-Velazquez, C; Montano-Loza, AJ; Rose, C, 2018) |
| "Sarcopenia is the loss of muscle mass and strength produced by aging or secondary to chronic diseases such as chronic liver disease (CLD)." | ( Abrigo, J; Aguirre, F; Andía, ME; Arrese, M; Cabello-Verrugio, C; Cabrera, D; Campos, F; Garcés, B; Karpen, S; Simon, F, 2018) |
| "Sarcopenia is present in a considerable proportion of patients with MIBC undergoing upfront cisplatin-based chemotherapy before planned RC." | ( D'Andrea, D; Kimura, S; Klatte, T; Mari, A; Resch, I; Shariat, SF, 2018) |
| " Sarcopenia is the decrease in skeletal muscle mass and muscular function that occurs with aging." | ( Kobayashi, H, 2018) |
| "Sarcopenia is a state of degenerative skeletal muscle wasting induced by cancer cachexia." | ( Fukuda, H; Iizuka, J; Ishihara, H; Kondo, T; Takagi, T; Tanabe, K; Yoshida, K, 2018) |
| "The evaluation of sarcopenia is also important for kidney transplant recipients." | ( Kimura, Y; Kinoshita, H; Koito, Y; Matsuda, T; Sugi, M; Tsukaguchi, H; Yanishi, M, 2019) |
| "Sarcopenia is involved in the pathogenesis of increased fracture risk associated with diabetes." | ( Fujii, H; Ide, H; Iwase, M; Jodai-Kitamura, T; Kitazono, T; Komorita, Y; Nakamura, U; Ohkuma, T; Sumi, A; Yoshinari, M, 2018) |
| "On the other hand, sarcopenia is one of the important prognostic factors of pancreatic cancer." | ( Endo, I; Goto, A; Ichikawa, Y; Kobayashi, N; Kubota, K; Kurita, Y; Nakajima, A; Tokuhisa, M, 2019) |
| "Sarcopenia is an independent indicator of poor prognosis in patients with pancreatic cancer who received FOLFIRINOX, while ATI and sarcopenic obesity predicted severe hematologic toxicity." | ( Endo, I; Goto, A; Ichikawa, Y; Kobayashi, N; Kubota, K; Kurita, Y; Nakajima, A; Tokuhisa, M, 2019) |
| "Sarcopenia is a robust prognostic indicator of outcomes after surgery for colorectal cancer (CRC)." | ( Dai, X; Feng, D; Gong, J; Li, J; Lv, T; Wang, X; Yang, J; Zhang, T; Zhu, W, 2019) |
| "Sarcopenia is related to poor prognosis and drug toxicities in solid tumors." | ( Çiçin, I; Demircan, NC; Erdoğan, B; Gökyer, A; Hacıoğlu, MB; İşsever, K; Köstek, O; Küçükarda, A; Solak, S; Sunal, BS; Uzunoğlu, S, 2019) |
| "Sarcopenia is highly prevalent in CKD/end stage renal disease patients and is associated with changes in early systemic indices of atherosclerosis and endothelial dysfunction, known as markers of worse prognosis." | ( Amabile, MI; Andreozzi, P; De Leo, S; Lai, S; Mazzaferro, S; Mitterhofer, AP; Molfino, A; Muscaritoli, M; Pasquali, M; Protopapa, P; Sgreccia, A; Spagnoli, A, 2019) |
| "Sarcopenia is a common complication of cirrhosis and is defined as a progressive and generalized loss of skeletal muscle mass, strength, and function." | ( Bhanji, RA; Montano-Loza, AJ; Watt, KD, 2019) |
| "Sarcopenia is a predictor of poor prognosis in cancer patients." | ( Ganju, RG; Hoover, A; Lominska, CE; Morse, R; TenNapel, M, 2019) |
| "Sarcopenia is an ageing-associated progressive and generalized loss of musculoskeletal mass and strength which leads to low physical performance, particularly in the frail elderly." | ( Beker, BM; Bertini, V; Musso, CG; Nicoletti, C, 2019) |
| "Sarcopenia is a common complication of cirrhosis with a negative impact on posttransplant outcome, health-related quality of life (HRQOL), and patient survival." | ( Butterworth, RF, 2019) |
| "Sarcopenia is closely related to short-term outcomes of surgery and long-term prognosis." | ( Fujimura, T; Fushida, S; Haba, Y; Harada, S; Kinoshita, J; Miyashita, T; Ohta, T; Oyama, K, 2019) |
| "Sarcopenia is an important health problem in older adults." | ( Artacho, R; Rodríguez-Rejón, AI; Ruiz-López, MD, 2020) |
| "sarcopenia is one of many geriatric problems that may lead to major clinical outcomes." | ( Ariane, A; Kurniawan, J; Laksmi, PW; Mienche, M; Setiati, S; Setyohadi, B; Tirtarahardja, G, 2019) |
| "Sarcopenia is characterized by the loss of muscle mass and strength (muscle atrophy) because of aging or chronic diseases, such as chronic liver disease (CLD)." | ( Abrigo, J; Aguirre, F; Arrese, M; Cabello-Verrugio, C; Cabrera, D; Marín, T; Simon, F; Tacchi, F; Vilos, C, 2019) |
| "Sarcopenia is a frequent complication in liver transplant (LT) recipients." | ( Albanese, C; D'Ambrosio, D; Farcomeni, A; Ginanni Corradini, S; Giusto, M; Lattanzi, B; Mennini, G; Merli, M; Rossi, M, 2019) |
| "Sarcopenia is a syndrome characterized by a progressive and generalized skeletal muscle mass and strength loss, as well as a poor physical performance, which as strongly been associated with aging." | ( Alarcón-Aguilar, A; Hernández-Álvarez, D; Hernández-Cruz, E; Ibañez-Contreras, A; Königsberg, M; Lazzarini-Lechuga, R; López-Cervantes, SP; López-Díazguerrero, NE; Luna-López, A; Mena-Montes, B; Morales-Salazar, A; Pedraza-Vázquez, G; Posadas-Rodríguez, P; Rosas-Carrasco, O; Santín-Márquez, R; Toledo-Pérez, R; Vázquez-Cárdenas, RR; Vilchis-DeLaRosa, S, 2019) |
| "Sarcopenia is a geriatric syndrome and it impairs physical function." | ( Cui, M; Gang, X; Jiang, Z; Li, Z; Wang, G; Xiao, X, 2020) |
| "Sarcopenia is an aging-induced deterioration of skeletal muscle mass and function." | ( Cheung, WH; Chim, YN; Chow, SK; Cui, C; Leung, KS; Shi, L; Wang, J; Wong, RMY; Xu, J; Yao, H, 2020) |
| "Sarcopenia is associated with adverse outcomes in several gastrointestinal malignancies and liver cirrhosis." | ( Attenberger, U; Block, W; Faron, A; Fimmers, R; Kuetting, DLR; Luetkens, JA; Meyer, C; Pieper, CC; Sprinkart, AM; Thomas, D, 2020) |
| "Sarcopenia is frequent in cirrhosis and impacts prognosis." | ( Bermudez, C; Crespo, G; Diaz, JM; Gadano, A; Garcia-Olveira, L; Gutierrez-Acevedo, MN; Marciano, S; Martinez-Garmendia, A; Mauro, E; Narvaez, A; Orta, R; Ortiz-Patron, J; Piano, S; Saidman, J; Savluk, L; Spina, JC; Zalazar, F, 2020) |
| "Sarcopenia is a poor prognosis factor in some cancer patients, but little is known about the mechanisms by which malignant tumors cause skeletal muscle atrophy." | ( Hara, T; Kaneda, Y; Kanemura, N; Kitagawa, J; Matsumoto, T; Mizutani, T; Nakamura, H; Nakamura, N; Ninomiya, S; Shimizu, M; Shiraki, M; Tsurumi, H; Yamaguchi, K, 2020) |
| "Sarcopenia is characterized by progressive loss of skeletal muscle and has frequently been associated with poor clinical outcomes in patients with advanced heart failure (HF)." | ( Anegawa, E; Fujita, T; Fukushima, N; Fukushima, S; Ito, H; Iwasaki, K; Kobayashi, J; Kuroda, K; Mochizuki, H; Murata, S; Nakajima, S; Nishimura, K; Seguchi, O; Sujino, Y; Watanabe, T; Yagi, N; Yanase, M; Yoshitake, K, 2020) |
| "Sarcopenia is a muscle disease featured by the loss of muscle mass and dysfunction with advancing age." | ( Hwang, JK; Kim, C, 2020) |
| "Sarcopenia is probably an independent risk factor for albuminuria in patients with T2DM." | ( Lin, C; Liu, C; Yan, J; Zheng, K, 2020) |
| "Sarcopenia is a recognised geriatric syndrome but few studies address its associated factors among elderly with type 2 diabetes mellitus (T2DM) in South East Asia." | ( A Hamid, MS; Chan, YM; Lee, PY; Sazlina, SG; Tan, NC, 2020) |
| "Sarcopenia is a progressive and generalized skeletal muscle disorder associated with an increased risk of adverse outcomes such as falls, disability, and death." | ( Bautmans, I; Beckwée, D; De Breucker, S; Delaere, A; Gielen, E; Vandewoude, M, 2021) |
| "Age-related sarcopenia is a progressive and generalized skeletal muscle disorder associated with adverse outcomes." | ( Boutry-Regard, C; Breuillé, D; Moritani, T; Vinyes-Parés, G, 2020) |
| "Sarcopenia is a geriatric syndrome characterised by progressive loss of skeletal muscle mass and function with risks of adverse outcomes and becomes more prevalent due to ageing population." | ( Cheng, KC; Cheng, KY; Cheung, WH; Chim, YN; Chow, SK; Ho, CY; Ho, WT; Wong, RM, 2020) |
| "Sarcopenia is common in patients with chronic obstructive pulmonary disease (COPD)." | ( Akimoto, K; Goto, Y; Hirai, K; Homma, T; Inoue, H; Miyata, Y; Ohta, S; Sagara, H; Suzuki, S; Tanaka, A; Uno, T; Yoshitaka, U, 2021) |
| "Sarcopenia is defined as a syndrome characterized by declines in skeletal muscle mass and strength or an alteration in physical function." | ( Chen, CD; Lin, CC; Shih, MH; Yeh, SL, 2021) |
| "Sarcopenia is defined as a progressive and generalized muscle disorder associated with certain physiological and pathological conditions." | ( Bas, V; Baysal, M; Demir, AM; Demirci, U; Durmus Altun, G; Karaman Gulsaran, S; Kirkizlar, HO; Korkmaz, U; Umit, EG, 2021) |
| "Introduction: sarcopenia is considered a risk factor for cancer patients, as it increases mortality and post-surgical complications, and reduces response to treatment and quality of life." | ( Guandalini, VR; Marques, RA; Pereira, TSS; Petarli, GB; Ribeiro, TSC; Rocha, JLM; Souza, VF, 2020) |
| "Sarcopenia is a common condition in older individuals, especially in the elderly with type 2 diabetes mellitus (T2DM)." | ( Cao, L; Chen, F; Huang, T; Liu, T; Ma, G; Wang, D; Wang, Y; Wei, Q; Xu, S; Zhao, Y, 2020) |
| "Sarcopenia is prevalent in patients with chronic kidney disease (CKD)." | ( Amano, M; Hasegawa, Y; Itoh, M; Kishimoto, H; Kusukawa, T; Kusunoki, H; Maeda, H; Nagai, K; Sano, K; Shimomura, S; Shinmura, K; Sugita, H; Tamaki, K; Tsuji, S; Wada, Y, 2021) |
| "Pre-sarcopenia is defined as transverse psoas muscle thickness per body height < 16." | ( Chao, Y; Chen, YT; Cheng, TY; Hou, MC; Huang, YH; Lee, PC, 2020) |
| "Sarcopenia is associated with lack of response to therapy, liver decompensation and higher mortality in hepatocellular carcinoma patients." | ( Alsebaey, A; Aly, RA; Badran, H; Elsabaawy, MM; Ragab, A; Sabry, A, 2020) |
| "Sarcopenia is highly prevalent among residents of assisted-living facilities." | ( Chen, CL; Chen, CY; Chen, FP; Lin, LL; Tseng, WC; Wong, AMK; Yang, YH, 2020) |
| "Sarcopenia is a condition which is defined by the gradual loss of skeletal muscle mass and function with age." | ( Bae, SJ; Dao, T; Gariani, K; Green, AE; Ha, KT; Kim, YA; Lee, MR; Menzies, KJ; Ryu, D, 2020) |
| "Sarcopenia is a common condition in older people and increasing evidence suggests that it can be considered as a potential risk factor for falls and fractures." | ( Barbagallo, M; Haro, JM; Koyanagi, A; Smith, L; Veronese, N; Yang, L; Zou, L, 2021) |
| "This process called sarcopenia is secondary to several factors such as sedentary lifestyle, inadequate nutrition, chronic inflammatory state and neurological alterations." | ( González-Hedström, D; Granado, M; López-Calderón, A; Martín, AI; Priego, T, 2021) |
| "Sarcopenia is an age-related disease that has gradually become a serious health problem for elderly individuals." | ( He, M; Hu, P; Jin, H; Li, Y; Tang, K; Wang, X; Wu, Y; Xie, W; Yu, D, 2021) |
| "The prevalence of sarcopenia is high in patients with type 2 diabetes mellitus (T2DM)." | ( Jin, C; Liu, J; Wang, C; Yin, X, 2021) |
| "Cachexia and sarcopenia are reported to be associated with reduced physical performance, reduced anti-tumor response, increased chemotherapy toxicity, and poor prognosis in several malignancies." | ( Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Suzumori, C; Takeda, T; Yamada, Y, 2021) |
| "Sarcopenia is a clinical syndrome that features muscle atrophy and weakness, and has been associated with cardiovascular events and poor clinical outcomes." | ( Chang, CC; Chou, RH; Huang, PH; Kuo, CS; Lin, SJ; Lu, YW; Tsai, YL, 2021) |
| "Sarcopenia is another target for the management of anemia in patients with hemodialysis." | ( Hamada, S; Isomoto, H; Iyama, T; Mae, Y; Takata, T; Taniguchi, S; Yamada, K; Yamamoto, M, 2021) |
| "Uremic sarcopenia is caused by ageing, malnutrition, and chronic inflammation, but the molecular mechanism and potential therapeutics have not been fully elucidated yet." | ( Higashihara, T; Inagi, R; Maruyama, T; Nangaku, M; Nishi, H; Takemura, K; Tanaka, T; Watanabe, H, 2021) |
| "Sarcopenia is a risk factor for poor outcomes in older adults." | ( Igase, M; Ochi, M; Ohyagi, Y; Okada, Y; Tabara, Y, 2021) |
| "Sarcopenia is one of the most common features of cirrhosis, contributing to morbidity and mortality in this population." | ( Colares, JR; da Fonseca, SRB; Dias, AS; Lehmann, M; Marroni, CA; Marroni, NAP; Martins, GDS; Miguel, FM; Picada, JN; Rosa, CGS, 2021) |
| "MELD-sarcopenia is better prognostic model than the ALBI and MELD scores in HCC patients awaiting liver transplantation." | ( Alsebaey, A; Aly, RA; Badran, H; Elsabaawy, MM; Ragab, A; Rashed, HS; Sabry, A, 2021) |
| "Sarcopenia is a prevalent condition in chronic kidney disease (CKD)." | ( Armelloni, S; Caldiroli, L; Callegari, ML; Margiotta, E; Messa, P; Miragoli, F; Rizzo, V; Vettoretti, S; Zanoni, F, 2021) |
| "Sarcopenia is considered an important risk factor for morbidity and mortality in liver cirrhosis." | ( Bruni, A; De Santis, A; Di Cola, S; Lattanzi, B; Merli, M; Molfino, A; Muscaritoli, M, 2021) |
| "Sarcopenia is a major health problem in older adults." | ( Chan, RS; Huang, D; Ma, SL; Tang, NL; Wang, X; Woo, J; Wu, J; Zhu, L, 2021) |
| "Osteoporosis and sarcopenia are two conditions associated with aging and characterized by a simultaneous decline in bone and muscle mass, respectively." | ( Duque, G; Hayes, A; Levinger, I; Mandelli, A; Tacconi, E, 2022) |
| "Sarcopenia is defined as a combination of low skeletal muscle mass index (SMI), weak muscle strength, and reduced physical function." | ( Amano, M; Hasegawa, Y; Igase, M; Itoh, M; Kishimoto, H; Kusunoki, H; Maeda, H; Nagai, K; Sano, K; Shimomura, S; Shinmura, K; Sugita, H; Tabara, Y; Tamaki, K; Tsuji, S; Wada, Y, 2022) |
| "Sarcopenia is defined as loss of volume and strength of skeletal muscle in elderlies, while frailty involves multiple domains of aging-related dysfunction, impaired cognition, hypomobility, and decreased social activity." | ( Kameda, M; Kondoh, H; Teruya, T; Yanagida, M, 2021) |
| "Sarcopenia is a process associated to aging." | ( Bello, HJ; Caballero-García, A; Córdova-Martínez, A; Noriega-González, DC; Pascual-Fernández, J; Pons-Biescas, A; Roche, E, 2021) |
| "Sarcopenia is strongly associated with long-term mortality in patients undergoing hemodialysis." | ( Hamada, S; Isomoto, H; Iyama, T; Mae, Y; Takata, T; Yamada, K; Yamamoto, M, 2022) |
| "Osteoporosis and sarcopenia are major health issues in postmenopausal women due to their high prevalence and association with several adverse outcomes." | ( Chen, M; Cheng, Q; Du, Y; Jiang, X; Li, H; Shi, H; Tang, W; Wu, X; Xu, C; Zhang, X, 2021) |
| "Sarcopenia is a clinical condition that comprises declined skeletal muscle (SM) mass and SM strength, and is a risk factor for physical disability, impaired quality of life, and advanced morbidity and mortality in patients on hemodialysis (HD)." | ( Andriopoulos, C; Drakou, A; Papachristou, E; Papachrysanthou, T; Papasotiriou, M; Papastamatiou, M; Plytzanopoulou, P; Politis, P, 2022) |
| "Sarcopenia is defined as the progressive and generalized loss of skeletal muscle mass and strength, which is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability, and mortality." | ( Eguchi, S; Hashimoto, T; Kingsley, J; Torimoto, K, 2021) |
| "Sarcopenia is a progressive and generalized skeletal muscle disorder with unfavorable muscle changes throughout life, which can be associated with chronic disease." | ( Bieger, P; Correa, C; Perry, IS; Souza, GC, 2022) |
| "Sarcopenia is the age-related loss of muscle mass and function and no pharmacological medication has been approved for its treatment." | ( Choi, JY; Kim, MJ; Kwak, JY; Kwon, KS; Lee, KP; Lee, SM; Lee, Y; Yang, JW; Yang, YR; Yoon, JH, 2022) |
| "Sarcopenia is a progressive and generalized skeletal muscle disorder characterized by muscle weakness, loss of muscle mass, and decline in the capacity of force generation." | ( Abrigo, J; Cabello-Verrugio, C; Cabrera, D; Simon, F; Vilos, C, 2022) |
| "The pathogenesis of sarcopenia is complex and has not been well explored." | ( Chang, CH; Chen, CY; Chen, GY; Kuo, CH; Tsai, JS; Tseng, YJ; Wang, SY; Wen, CJ, 2022) |
| "Sarcopenia is an important factor in the postoperative outcome of gastrointestinal cancer patients." | ( Hawke, P; Higashizono, K; Kanemoto, H; Nagai, E; Nakatani, E; Oba, N; Takagi, A; Toda, T; Tokuda, S; Watanabe, M, 2022) |
| "Sarcopenia is an important prognostic factor for cancer patients." | ( Ashida, R; Emori, T; Hatamaru, K; Itonaga, M; Kawai, M; Kawaji, Y; Kitano, M; Koike, M; Shimokawa, T; Sonomura, T; Tamura, T; Yamashita, Y, 2022) |
| "Sarcopenia is an independent indicator of a poor prognosis in patients with PDAC treated with first-line GEM and nab-PTX." | ( Ashida, R; Emori, T; Hatamaru, K; Itonaga, M; Kawai, M; Kawaji, Y; Kitano, M; Koike, M; Shimokawa, T; Sonomura, T; Tamura, T; Yamashita, Y, 2022) |
| "Sarcopenia is an age-related syndrome that may have negative impact on surgical outcomes and long-term survival of patients with gastric cancer." | ( Cai, W; Chen, X; Pan, B; Shen, N; Shen, X; Sun, J; Yang, H; Yang, X; Zhang, W; Zheng, J, 2022) |
| "Management of sarcopenia is a vital factor for improving survival outcomes in patients with HCC." | ( Cui, GZ; Dong, D; Liu, B; Shang, X; Shi, JY; Wang, NY; Xu, WL, 2022) |
| "Sarcopenia is the decline in muscle strength and mass attributed to aging." | ( Chen, X; Dong, B; Hou, L; Hu, F; Liu, X; Luo, S; Peng, X; Sun, X; Xia, X; Yue, J; Zhang, G, 2022) |
| "Sarcopenia is characterized by loss of muscle strength and physical ability because of aging and/or chronic disease." | ( Dos Santos, MR; Storer, TW, 2022) |
| "Sarcopenia is associated with poor clinical outcomes of patients who underwent esophagectomy." | ( Ge, QY; Hu, LW; Li, JS; Luo, C; Shen, Y; Wang, E; Xie, K; Zheng, C, 2022) |
| "Sarcopenia is an important prognostic factor of lung cancer." | ( Hu, S; Lei, X; Luo, X; Tan, L; Tang, T; Xie, L; Yang, L; Yang, M, 2022) |
| "Uremic sarcopenia is a serious clinical problem associated with physical disability and increased morbidity and mortality." | ( Hosoda, Y; Miyazaki, M; Mori, T; Sato, E; Sato, H; Sekimoto, A; Takahashi, N; Todoriki, S; Watanabe, M; Yamamoto, T, 2022) |
| "Sarcopenia is characterized as an age-related loss of muscle mass that results in negative health consequences such as decreased strength, insulin resistance, slowed metabolism, increased body fat mass, and a substantially diminished quality of life." | ( Baskaran, R; Chang, CF; Chen, YJ; Lin, WT; Mohammedsaleh, ZM, 2022) |
| "Sarcopenia is a condition that is highly prevalent among older adults." | ( Ahmad, NS; Ali, ZM; Bulgiba, A; Choo, WY; Hairi, FM; Hairi, NN; Ismail, N; Kandiben, S; Peramalah, D; Ramoo, K; Razak, IA; Yahya, A, 2022) |
| "Sarcopenia is a geriatric condition characterized by progressive loss of skeletal muscle mass and function." | ( Honda, S; Ishikawa, S; Murohara, T; Sekino, T; Shibata, R; Takemoto, K; Uemura, Y; Watarai, M, 2022) |
| "Diabetes and sarcopenia are verified as mutual relationships, which seriously affect the quality of life of the elderly." | ( Chen, CM; Huang, PJ; Lee, IT; Tsai, CH; Wu, MH, 2022) |
| "Sarcopenia is well recognized as a prognostic factor of chronic liver diseases." | ( Chayama, K; Ito, M; Kanno, K; Kikuchi, Y; Kimura, H; Miyamori, D; Serikawa, M; Tazuma, S; Yoshimura, K, 2022) |
| "Sarcopenia is a status with increasing importance in lung cancer, and it may predict a poor prognosis." | ( Besiroglu, M; Ozturk, A; Seker, M; Topcu, A; Turk, HM; Yasin, AI; Yurtsever, I, 2022) |
| "Sarcopenia is associated with other age-related conditions such as osteoporosis, frailty and cachexia." | ( Candow, DG; Chilibeck, PD; Fairman, CM; Forbes, SC; Gualano, B; Roschel, H, 2022) |
| "Aging-related sarcopenia is currently the most common sarcopenia." | ( Chen, J; Guo, A; Liao, Z; Sun, Y; Wu, J; Wu, Y; Xiao, Q; Yang, Y; Yu, J; Zhao, Y, 2022) |
| "Sarcopenia is prevalent in patients with chronic kidney disease (CKD), which is defined as a low estimated glomerular filtration rate (eGFR)." | ( Hasegawa, Y; Kishimoto, H; Kusunoki, H; Matsuzawa, R; Mori, T; Nagai, K; Shimizu, H; Shinmura, K; Tamaki, K; Tsuji, S; Wada, Y, 2022) |
| "Sarcopenia is an age-related condition of slow, progressive loss of muscle mass and strength, which contributes to frailty, increased risk of hospitalization and mortality, and increased health care costs." | ( Alves, FM; Ayton, S; Bush, AI; Koopman, R; Lynch, GS, 2023) |
| "Sarcopenia is a known predictor of overall survival in several diseases." | ( Anai, S; Fujimoto, K; Hori, S; Miyake, M; Nakai, Y; Onishi, K; Tanaka, N, 2022) |
| "Sarcopenia is defined as low muscle mass, with low muscle strength." | ( Carneiro, A; Correia-Neves, M; Cotter, J; Cunha, C; Cunha, P; Ferreira, J; Longatto-Filho, A; Mansilha, A; Mesquita, A; Silva, C; Vila, I, 2023) |
| "Sarcopenia is an important comorbidity in patients with heart failure with preserved ejection fraction (HFpEF)." | ( Bernal-López, MR; Cuesta-Vargas, AI; Fuentes-Abolafio, IJ; Gómez-Huelgas, R; Pérez-Belmonte, LM; Ricci, M, 2022) |
| "Sarcopenia is a major cause of disability in the elderly." | ( Kadowaki, S; Kaga, H; Kakehi, S; Kawamori, R; Naito, H; Sato, M; Someya, Y; Sugimoto, D; Suzuki, R; Tabata, H; Tamura, Y; Watada, H; Yamasaki, N, 2022) |
| "Sarcopenia is frequent in liver cirrhosis (LC) where it is associated with morbidity and mortality." | ( Hentschel, F; Lüth, S; Schreyer, AG; Schwarz, T, 2022) |
| "Sarcopenia is a disabling muscular multifactorial disease involving the oxidation process in old-young adults." | ( Besora-Moreno, M; Llauradó, E; Pedret, A; Solà, R; Tarro, L; Valls, RM, 2022) |
| "Sarcopenia is reported to be associated with depression." | ( Guo, X; Shi, X; Yang, Y; Zhang, Q; Zhang, X; Zhu, Y, 2022) |
| "Sarcopenia is associated with various adverse outcomes in hemodialysis patients." | ( Cai, G; Lang, X; Pan, M; Ying, J; Yu, W; Zhang, Q, 2022) |
| "Sarcopenia is a common chronic disease characterized by age-related decline in skeletal muscle mass and function, and the lack of diagnostic biomarkers makes community-based screening problematic." | ( Cai, X; Chen, C; Fan, Y; Lin, S; Ling, M; Yang, F, 2022) |
| "Sarcopenia is a precursor for physical frailty and is associated with adverse outcomes." | ( Ho, V; Lee, CT; Merchant, RA, 2022) |
| "Sarcopenia is an age-related accelerated loss of muscle strength and mass." | ( Chen, G; Chen, J; Huang, W; Luan, X; Mo, C; Shen, J; Tan, H; Wang, Y; Xu, X; Yang, R; Yang, X, 2022) |
| "Sarcopenia is a complication of Chronic Obstructive Pulmonary Disease (COPD) that negatively affects physical activity and quality of life." | ( Azuma, K; Kawai, K; Kawasaki, M; Kosugi, K; Kozaki, K; Li, YS; Mano, Y; Nabeshima, T; Nakamura, E; Nakashima, T; Nakazato, K; Sakai, A; Suzuki, H; Tajima, T; Tamura, Y; Tsukamoto, M; Wang, KY; Yamanaka, Y; Yatera, K; Zhou, Q, 2022) |
| "Sarcopenia is significantly more common in patients with RA compared with controls using the EWGSOP2 criteria." | ( Armbrecht, G; Borucki, D; Buehring, B; Buttgereit, F; Detzer, C; Dietzel, R; Schaumburg, D; Wiegmann, S; Zeiner, KN, 2022) |
| "Sarcopenia is observed in about 50% of cancer patients." | ( Deluche, E; Di Palma, M; Durand, JP; Goldwasser, F; Pigneur, F; Raynard, B; Revel, MP; Tlemsani, C, 2022) |
| "Sarcopenia is a common complication in patients with end-stage kidney disease." | ( Chen, R; Jin, H; Li, Z; Liu, B; Liu, D; Liu, H; Wang, Y; Zhang, L; Zhang, M; Zhang, X, 2022) |
| "Hepatic sarcopenia is one of many complications associated with chronic liver disease (CLD) and has a high mortality rate; however, the liver-muscle axis is not fully understood." | ( Eguchi, A; Iwasa, M; Kitamura, H; Kobayashi, Y; Nakagawa, H; Shigefuku, R; Sugimoto, R; Takei, Y; Tamai, Y; Tempaku, M, 2022) |
| "BACKGROUND Sarcopenia is a common complication in maintenance hemodialysis (MHD) and can increase patient hospitalization and mortality." | ( Chen, G; Du, X; Gu, F; Liu, Y; Wang, Y; Yin, L; Zhang, H, 2022) |
| "Sarcopenia is a clinically relevant syndrome with health, social, and economic implications." | ( Cong, M; Guo, L; Khatun, P; Kong, Y; Liang, R; Lyu, Q; Ma, B; Qin, J; Zhai, J, 2022) |
| "Sarcopenia is the decline in skeletal muscle mass, strength, and functions, which decreases the quality of life in elderly people." | ( Furukawa, K; Jia, H; Kato, H; Kousaka, M, 2022) |
| "Sarcopenia is a progressive syndrome that results in a decline in skeletal muscle mass and strength." | ( Gong, W; Kim, W; Li, H; Li, L; Sun, Y; Zha, W, 2022) |
| "Sarcopenia is a common skeletal muscle disorder in the elderly population." | ( Chen, WL; Chen, YY; Yang, SW, 2022) |
| "Sarcopenia is an important risk factor for hip fracture in older people." | ( Artacho, R; Borges, K; Jodar-Graus, R; Molina-Montes, E; Ruiz-López, MD, 2022) |
| "Sarcopenia is an age-related geriatric syndrome characterized by the gradual loss of muscle mass and function." | ( Bao, Z; Cheung, WH; Chow, SK; Cui, C; Qin, L; Welch, A; Wong, RMY, 2022) |
| "Sarcopenia is a complex process characterized by a progressive decrease in muscle mass and strength." | ( Barrile, GC; Battaglia, S; Cavioni, A; Gasparri, C; Giusti, R; Mansueto, F; Moroni, A; Nannipieri, F; Patelli, Z; Perna, S; Razza, C; Rondanelli, M; Tartara, A, 2022) |
| "Sarcopenia is common in patients with Parkinson's disease (PD), showing mitochondrial oxidative stress in skeletal muscle." | ( Chan, P; Lu, J; Pang, S; Wang, Y; Yang, Q; Zhao, C, 2023) |
| "Sarcopenia is common in patients with Parkinson's disease (PD), showing mitochondrial oxidative stress in skeletal muscle." | ( Chan, P; Lu, J; Pang, S; Wang, Y; Yang, Q; Zhao, C, 2023) |
| "Sarcopenia is common in patients with Parkinson's disease (PD), showing mitochondrial oxidative stress in skeletal muscle." | ( Chan, P; Lu, J; Pang, S; Wang, Y; Yang, Q; Zhao, C, 2023) |
| "Sarcopenia is an age-related skeletal muscle disorder that involves a loss of muscle mass or strength and physiological function." | ( Chen, Y; Cui, T; Deng, Y; Ding, F; Han, Y; He, Y; Hou, L; Huang, C; Liu, Q; Yin, M; Yue, J; Zhang, H, 2022) |
| "Sarcopenia is an age-related skeletal muscle disorder that involves a loss of muscle mass or strength and physiological function." | ( Chen, Y; Cui, T; Deng, Y; Ding, F; Han, Y; He, Y; Hou, L; Huang, C; Liu, Q; Yin, M; Yue, J; Zhang, H, 2022) |
| "Sarcopenia is an age-related skeletal muscle disorder that involves a loss of muscle mass or strength and physiological function." | ( Chen, Y; Cui, T; Deng, Y; Ding, F; Han, Y; He, Y; Hou, L; Huang, C; Liu, Q; Yin, M; Yue, J; Zhang, H, 2022) |
| "Sarcopenia is a condition in which muscle mass, strength, and performance decrease with age." | ( Jang, YJ, 2023) |
| "Sarcopenia is a condition in which muscle mass, strength, and performance decrease with age." | ( Jang, YJ, 2023) |
| "Primary sarcopenia is a multicausal skeletal muscle disease associated with muscle strength and mass loss." | ( Fu, R; Li, Y; Sun, Y; Wu, Y; Xiao, Q; Yu, J; Zhang, Y; Zhao, K, 2023) |
| "Sarcopenia is one of the most predominant musculoskeletal diseases of the elderly, defined as age-related progressive and generalized loss of muscle mass with a simultaneous reduction in muscle strength and/or function." | ( Baber, L; Bidlingmaier, M; Drey, M; Ferrari, U; Hofmeister, F; Jarmusch, S; Koletzko, B; Marques, J; Shokry, E; Uhl, O, 2023) |
| "Although sarcopenia is mainly caused by aging, sarcopenia due to obesity has become an emerging issue given the increase in obesity among people of various ages." | ( Kim, JW; Kwon, EY; Shin, SK, 2023) |
| "Sarcopenia is a geriatric syndrome with progressive loss of skeletal muscle mass and function and has a negative impact on clinical outcomes associated with chronic obstructive pulmonary disease (COPD)." | ( Chen, M; Chen, Y; Hu, R; Huang, D; Li, D; Su, R; Wu, B; Wu, D; Xu, X; Yang, Y; Yuan, Y; Zhang, J; Zhang, W; Zhao, X, 2023) |
| "Sarcopenia is a senile disease with high morbidity, serious complications and limited clinical treatments." | ( Hua, Y; Huang, Y; Ling, L; Shu, H; Xiong, Z; Zhang, W, 2023) |
| "Osteosarcopenia is the progressive loss of musculoskeletal structure and functionality, contributing to disability and mortality." | ( Briones, J; Emmenegger, U; Hardisty, MR; Khan, M; Lyons, F; Naimi, MF; Parshad, S; Phillips, CM; Sidhu, AK; Smoragiewicz, M; Whyne, CM, 2023) |
| "Sarcopenia is defined by the progressive and generalized loss of muscle mass and function associated with aging." | ( Alcalde-Estévez, E; Asenjo-Bueno, A; López-Ongil, S; Naves-Díaz, M; Olmos, G; Plaza, P; Ruiz-Torres, MP; Sosa, P; Valenzuela, PL, 2023) |
| "Sarcopenia is a risk factor for poor cancer prognosis." | ( Chen, N; Lei, S; Long, L; Luo, X; Luo, Y; Peng, H; Sun, S; Xiong, Y; Yuan, H; Zhang, Q, 2023) |
| "Sarcopenia is a geriatric syndrome characterized by an age-related decline in skeletal muscle mass and strength." | ( Abe, T; Higashitani, A; Itoh, Y; Kobayashi, T; Kubota, Y; Nakagawa, Y; Sudevan, S; Szewczyk, NJ; Teranishi, M, 2023) |
| "Sarcopenia is an age-related syndrome characterized by a gradual loss of the muscle mass, strength, and function." | ( Du, G; He, P; Li, Z; Qin, X, 2023) |
| "Sarcopenia is defined as loss of muscle mass and strength due to aging." | ( Chung, Y; Kang, M; Kim, JN; Lee, J; Lee, S; Moon, H; Oh, S; Yoo, J; Yun, B, 2023) |
| "Sarcopenia is associated with worse outcomes in maintenance hemodialysis (MHD) patients." | ( Hasan, I; Jauwerissa, R; Laksmi, PW; Marbun, MBH; Nugroho, P; Rinaldi, I; Shatri, H; Suhardjono, S, 2023) |
| "Sarcopenia is an age-related skeletal muscle disorder characterized by loss of muscle mass and strength leading to mobility disability." | ( Balducci, C; Daudigny, L; Del Signore, S; Dilda, PJ; Dioh, W; Dupont, P; Lafont, R; Tourette, C; Veillet, S, 2023) |
| "Sarcopenia is an emerging public health problem worldwide, but very limited information exits concerning the influence of lifestyle factors and inflammation on sarcopenia among community-dwelling older populations in Asia, including Malaysia." | ( Foo, LH; Kadir, AA; Wen, YS, 2023) |
| "Sarcopenia is a significant concern for HNC patients and can impact their clinical outcomes." | ( Aksoy, S; Erul, E; Guven, DC; Onur, MR; Yazici, G, 2023) |
| "Sarcopenia is recognized as a major public health concern because of its association with several adverse health events." | ( Chen, X; Jia, H; Jiang, W; Li, T; Pan, Q; Song, Y; Wang, M; Yang, C; Zhou, J, 2023) |
| "Sarcopenia is one of the primary risk factors for various adverse health events in later life." | ( Abe, Y; Arai, Y; Candia, J; Oguma, Y; Osawa, Y; Tajima, T, 2023) |
| "Sarcopenia is the progressive loss of muscle mass, strength, and functions as we age." | ( Aminuddin, A; Chin, KY; Makpol, S; Saud Gany, SL; Tan, JK, 2023) |
| "Sarcopenia is prevalent among the older population and severely affects human health." | ( Guo, Y; Wang, D; Wang, T; Wu, S; Xu, H; Zhao, G, 2023) |
| "Sarcopenia is an age-related disease that mainly involves decreases in muscle mass, muscle strength and muscle function." | ( Feng, W; Lai, J; Li, Y; Lu, W; Xiao, W; Yuan, D, 2023) |
| "Sarcopenia is a geriatric syndrome characterized by decreased physical performance, muscle mass, and strength." | ( Abe, Y; Hiyoshi, T; Inoue, I; Kaga, H; Kuribayashi, N; Seino, H; Tamura, Y; Watada, H; Yoshii, H, 2023) |
| "Sarcopenia is a common skeletal muscle degenerative disease characterized by decreased skeletal muscle mass and mitochondrial dysfunction that involves microRNAs (miR) as regulatory factors in various pathways." | ( Chen, ZL; Feng, C; Guo, C; Jian, ZJ; Peng, XY; Sun, CC; Tang, CF; Wen, W; Xiao, Q; Yang, DX; Zhao, Z; Zheng, L; Zhou, ZQ; Zou, YY, 2023) |
| "Sarcopenia is highly prevalent in elderly individuals and has a significant adverse effect on their physical health and quality of life, but the mechanisms remain unclear." | ( Cai, X; Chen, W; Jia, X; Ma, B; Mao, L; Yu, D; Yu, Z; Zhang, F; Zhang, X; Zhu, G; Zhuang, C, 2023) |
| "Sarcopenia is a frequent comorbidity of rheumatoid arthritis (RA)." | ( Bermejo-Álvarez, I; Gratal, P; Herrero-Beaumont, G; Largo, R; Mediero, A; Medina, JP; Pérez-Baos, S, 2023) |
| "Muscle wasting (sarcopenia) is one of the hallmarks of critical illness." | ( Annetta, MG; De Rosa, S; Greco, M; Rauseo, M, 2023) |
| "Sarcopenia is a progressive muscle disease characterized by the loss of skeletal muscle mass, strength, function, and physical performance." | ( Kim, CY; Kim, NH; Lee, JY, 2023) |
| "Sarcopenia is an age-related, multifactorial syndrome." | ( Chang, KH; Chen, CY; Chen, SW; Hsieh, TL; Lin, CL; Lin, CY; Tsai, FJ, 2023) |
| "Sarcopenia is characterised by losses in both muscle mass and strength." | ( Achison, M; Adamson, S; Akpan, A; Aspray, T; Avenell, A; Band, MM; Bashir, T; Burton, LA; Cvoro, V; Donnan, PT; Duncan, GW; George, J; Gordon, AL; Gregson, CL; Hapca, A; Hume, C; Jackson, TA; Kemp, PR; Kerr, S; Kilgour, A; Masud, T; McKenzie, A; McKenzie, E; Patel, H; Pilvinyte, K; Roberts, HC; Rossios, C; Sayer, AA; Smith, KT; Soiza, RL; Steves, CJ; Struthers, AD; Tiwari, D; Whitney, J; Witham, MD, 2023) |
| "Sarcopenia is defined as the disease of muscle loss and dysfunction." | ( Cheng, ML; Fan, CM; Ho, HY; Lin, CM; Liu, HF; Lo, CJ; Tang, HY, 2023) |
| "Sarcopenia is a crucial factor in assessing the nutritional status of chronic liver disease patients and predicting their prognosis and survival." | ( Seo, KI, 2023) |
| "The onset of sarcopenia is associated with a decline in vitamin D receptor (VDR) expression, wherein reduced VDR levels contribute to muscle atrophy, while heightened expression promotes muscle hypertrophy." | ( Kim, KS; Talib, NF; Zhu, Z, 2023) |